SHANGHAI, Sept. 16 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics" or "the Company"), the leading developer, manufacturer and distributor of probiotics products in China, today announced that it has submitted two new patent applications to the State Bureau of Intellect Property.
The Company's wholly owned subsidiary, Growing Bioengineering (Shanghai) Co. Ltd., located in the Qingpu Industrial Zone, has filed two applications in the areas of heat resistant fermentation technology and probiotics protein beverage.
Mr. Jinan Song, Chairman and CEO of China-Biotics, concluded, "We continue to focus on the development of our proprietary technologies and products to heighten entry barriers for our competitors. After we successfully implemented our incentive plan for product development and production innovations, our sales team and R&D team are now working more closely with each other to develop new products, cut costs and increase productivities. Also, we will be launching more joint R&D programs with leading research institutions in China. Our goal remain intact, to provide the best comprehensive probiotics solutions to our end customers. As the Chinese government continues to address food safety measures and Chinese consumers are increasing their healthcare expenditures, we expect that more and more dairy and animal feed companies will embrace and increase the use of our probiotics products."
China-Biotics, Inc. ("China-Biotics" or "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Through its wholly owned subsidiaries, Shanghai Shining Biotechnology Co., Ltd. and Growing Bioengineering (Shanghai) Co. Ltd., the Company develops and produces its proprietary product portfolio. Currently, the retail products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. The Company also sells bulk products to institutional customers such as dairy and animal feed producers, as well as pharmaceutical companies. In February 2010, China-Biotics began its commercial production in China's largest probiotics production facility to meet growing demand in China. For more information, please visit http://www.chn-biotics.com .
Safe Harbor Statement
The information in this release contains forward-looking statements which involve risks and uncertainties, including statements regarding the Company's capital needs, business strategy and expectations. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, which may be identified by terminology such as "may," "should," "will," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "forecast," "project," "continue," or the negative of such terms or other comparable terminology. Readers should not rely on forward-looking statements as predictions of future events or results. Any or all of the Company's forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions, risks and uncertainties and other factors which could cause actual events or results to be materially different from those expressed or implied in the forward-looking statements. In evaluating these statements, readers should consider various factors, including the risks described in "Item 1A. Risk Factors" beginning on page 17 and elsewhere in the Company's 2010 Annual Report on Form 10-K. These factors may cause the Company's actual results to differ materially from any forward-looking statement. In addition, new factors emerge from time to time and it is not possible for the Company to predict all factors that may cause actual results to differ materially from those contained in any forward-looking statements. The Company disclaims any obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this document, except as required by applicable law.
For more information, please contact: China-Biotics, Inc. Travis Cai Chief Financial Officer Email: firstname.lastname@example.org Grayling Kevin Theiss / Shiwei Yin Tel: +1-646-284-9409 Email: kevin.theiss@grayling. com email@example.com
|SOURCE China-Biotics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved